Literature DB >> 6444389

Elastic properties of normal and hypertrophied cardiac muscle.

I Mirsky, A Pasipoularides.   

Abstract

This brief review addresses itself to the following questions on normal and hypertrophied muscle. 1) What changes, if any, take place in the mechanical properties of cardiac muscle during pressure and volume overload hypertrophy? 2) What parameters may signal preoperatively irreversibility of hypertrophy and chamber enlargement? 3) Are the effects of age and hypertrophy on muscle stiffness similar? 4) What relationships exist between diastolic properties and systolic function? The analyses of the elastic properties of cardiac muscle based on several animal and clinical studies indicate that: a) Muscle stiffness in pressure overload is elevated and is normal in volume overload in the majority of the animal studies. However, the clinical studies support the hypothesis that muscle stiffness remains normal in mild to moderate degrees of valvular disease and is elevated in severe valvular disease. b) Wall stress, volume:mass, and radius:thickness ratios are useful prognostic indicators regarding reversibility of wall hypertrophy and/or chamber enlargement. c) Effects of age and hypertrophy on muscle stiffness are similar for the age range of young adult (6 mo) to old (90 wk) SHR and WKY rats. d) Increased muscle stiffness is invariably accompanied by decreased muscle shortening velocity but rate of force development and peak force may not be impaired.

Entities:  

Mesh:

Year:  1980        PMID: 6444389

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  16 in total

1.  RV functional imaging: 3-D echo-derived dynamic geometry and flow field simulations.

Authors:  Ares D Pasipoularides; Ming Shu; Michael S Womack; Ashish Shah; Olaf Von Ramm; Donald D Glower
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09-12       Impact factor: 4.733

Review 2.  Cardiac mechanics: basic and clinical contemporary research.

Authors:  A Pasipoularides
Journal:  Ann Biomed Eng       Date:  1992       Impact factor: 3.934

Review 3.  Clinical-pathological correlations of BAV and the attendant thoracic aortopathies. Part 2: Pluridisciplinary perspective on their genetic and molecular origins.

Authors:  Ares Pasipoularides
Journal:  J Mol Cell Cardiol       Date:  2019-06-06       Impact factor: 5.000

4.  Mechanotransduction Mechanisms for Intraventricular Diastolic Vortex Forces and Myocardial Deformations: Part 2.

Authors:  Ares Pasipoularides
Journal:  J Cardiovasc Transl Res       Date:  2015-05-14       Impact factor: 4.132

Review 5.  Fluid dynamic aspects of ejection in hypertrophic cardiomyopathy.

Authors:  Ares Pasipoularides
Journal:  Hellenic J Cardiol       Date:  2011 Sep-Oct

6.  Quantification of myocardial stiffness using magnetic resonance elastography in right ventricular hypertrophy: initial feasibility in dogs.

Authors:  Juliana S da Silveira; Brian A Scansen; Peter A Wassenaar; Brian Raterman; Chethan Eleswarpu; Ning Jin; Xiaokui Mo; Richard D White; John D Bonagura; Arunark Kolipaka
Journal:  Magn Reson Imaging       Date:  2015-10-22       Impact factor: 2.546

Review 7.  Calcific Aortic Valve Disease: Part 1--Molecular Pathogenetic Aspects, Hemodynamics, and Adaptive Feedbacks.

Authors:  Ares Pasipoularides
Journal:  J Cardiovasc Transl Res       Date:  2016-02-18       Impact factor: 4.132

8.  Right ventricular diastolic function in canine models of pressure overload, volume overload, and ischemia.

Authors:  Ares Pasipoularides; Ming Shu; Ashish Shah; Scott Silvestry; Donald D Glower
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

9.  Know Me! Unraveling the Riddle of Calcific Aortic Valve Disease by Bioinformatics.

Authors:  Ares Pasipoularides
Journal:  Tohoku J Exp Med       Date:  2017-12       Impact factor: 1.848

Review 10.  Calcific Aortic Valve Disease: Part 2-Morphomechanical Abnormalities, Gene Reexpression, and Gender Effects on Ventricular Hypertrophy and Its Reversibility.

Authors:  Ares Pasipoularides
Journal:  J Cardiovasc Transl Res       Date:  2016-05-16       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.